CONNECT-FX Used Blood DNA to Classify FMR1 Methylation, Not to Measure THC Exposure
The blood-based methylation classification in CONNECT-FX was genetic laboratory information. It was not a cannabinoid toxicology result or a blood THC concentration.
The sampled material answered a molecular question
The study isolated genomic DNA from peripheral blood leukocytes. Molecular testing characterized CGG repeat size, the proportion of methylated FMR1 alleles and, in females, activation ratio. These measurements supported characterization of fragile X syndrome and exploratory subgroup analyses.
A percentage requires its actual denominator
At least 90% methylation described the molecular classification used for a subgroup. It did not mean 90% treatment response, 90% CBD absorption or 90% certainty of benefit. The behavioral outcome still came from rating scales over the treatment period, rather than directly from that laboratory percentage.
Biological classification and treatment evidence remain distinct
The full trial’s primary comparison was nonsignificant, while the methylation analyses generated a narrower hypothesis. Blood-based classification can make a subgroup biologically interesting without converting an exploratory result into confirmatory efficacy. An expert discussing the study should identify the analyte and method before assigning meaning to the word blood. DNA testing, cannabinoid concentration testing and behavioral assessment concern different questions, even when all involve the same participant. None of the methylation results supplies evidence of acute cannabis exposure or functional impairment.
Related analysis: the trial’s main results and limitations.
